New Korean Fund Aims For Stem Cell, Gene Therapy Edge
This article was originally published in PharmAsia News
Executive Summary
As some local biosimilar firms such as Celltrion have already got their feet firmly on the ground, the South Korean government is now shifting its strategic focus to support for stem cell and gene therapy ventures to help them advance into a global market where no clear leader has yet emerged.